ArticlePloS one2021

Potential negative impact of reputed regulators' decisions on the approval status of new cancer drugs in Latin American countries: A descriptive analysis.

Carlos E Durán et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.